FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082084811> ?p ?o ?g. }

• W3082084811 endingPage "1934" @default.
• W3082084811 startingPage "1928" @default.
• W3082084811 abstract "IntroductionRET rearrangements are an emerging targetable oncogenic fusion driver in NSCLC. However, the natural history of disease and activity of different classes of systemic therapy remain to be defined. Furthermore, molecular testing for RET is not yet routine, and the optimal method of testing is unclear. We present a comparative analysis of molecular profiling with fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) and treatment outcomes.MethodsThis study was a retrospective analysis of patients treated at the National Cancer Centre Singapore. Baseline demographics and treatment outcomes were collected.ResultsA total of 64 patients were included, with a median age of 62 years (range: 25–85), 56% were women, 77% were of Chinese ethnicity, 95% had adenocarcinoma, and 69% were never smokers. RET rearrangement was detected by FISH in 30 of 34 patients (88%), NGS in 40 of 43 patients (93%), and with discordant results in seven of 13 patients (54%) tested with both methods. Of 61 patients with stage IIIB/IV or recurrent disease, prevalence of central nervous system metastases was 31% and 92% received palliative systemic therapy. Overall survival was prolonged in patients treated with a selective RET tyrosine kinase inhibitor versus untreated patients (median 49.3 versus 15.3 mo; hazard ratio [HR]: 0.16, 95% confidence interval [CI]: 0.06–0.40, p < 0.001). However, it was not different in patients treated with immunotherapy versus untreated patients (median 37.7 versus 49.3 mo; HR: 1.30, 95% CI: 0.53–3.19, p = 0.53). Overall survival was also prolonged in patients with CCDC6-RET fusion versus those with KIF5B-RET fusion (median 113.5 versus 37.7 mo; HR: 0.12, 95% CI: 0.04–0.38, p = 0.009).ConclusionsIn RET-rearranged NSCLC, selective RET tyrosine kinase inhibitor therapy is associated with improved survival outcomes, especially in patients with CCDC6-RET fusion. However, immunotherapy has poor efficacy. NGS and FISH testing methods may also result in substantial discordance." @default.
• W3082084811 created "2020-09-08" @default.
• W3082084811 creator A5006952434 @default.
• W3082084811 creator A5007550309 @default.
• W3082084811 creator A5014671025 @default.
• W3082084811 creator A5015003014 @default.
• W3082084811 creator A5017520870 @default.
• W3082084811 creator A5025416634 @default.
• W3082084811 creator A5030515491 @default.
• W3082084811 creator A5040195943 @default.
• W3082084811 creator A5043046640 @default.
• W3082084811 creator A5044945171 @default.
• W3082084811 creator A5048241163 @default.
• W3082084811 creator A5069464289 @default.
• W3082084811 creator A5073819873 @default.
• W3082084811 creator A5077867618 @default.
• W3082084811 creator A5083527183 @default.
• W3082084811 creator A5084740033 @default.
• W3082084811 creator A5085784504 @default.
• W3082084811 creator A5088403164 @default.
• W3082084811 creator A5088791005 @default.
• W3082084811 creator A5089094058 @default.
• W3082084811 creator A5090148132 @default.
• W3082084811 date "2020-12-01" @default.
• W3082084811 modified "2023-10-01" @default.
• W3082084811 title "Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC" @default.
• W3082084811 cites W1964917847 @default.
• W3082084811 cites W1990626198 @default.
• W3082084811 cites W2050249255 @default.
• W3082084811 cites W2062291041 @default.
• W3082084811 cites W2065799563 @default.
• W3082084811 cites W2067813423 @default.
• W3082084811 cites W2320121320 @default.
• W3082084811 cites W2600348349 @default.
• W3082084811 cites W2784371446 @default.
• W3082084811 cites W2784623697 @default.
• W3082084811 cites W2796292093 @default.
• W3082084811 cites W2963477960 @default.
• W3082084811 cites W2981697998 @default.
• W3082084811 doi "https://doi.org/10.1016/j.jtho.2020.08.011" @default.
• W3082084811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32866654" @default.
• W3082084811 hasPublicationYear "2020" @default.
• W3082084811 type Work @default.
• W3082084811 sameAs 3082084811 @default.
• W3082084811 citedByCount "29" @default.
• W3082084811 countsByYear W30820848112020 @default.
• W3082084811 countsByYear W30820848112021 @default.
• W3082084811 countsByYear W30820848112022 @default.
• W3082084811 countsByYear W30820848112023 @default.
• W3082084811 crossrefType "journal-article" @default.
• W3082084811 hasAuthorship W3082084811A5006952434 @default.
• W3082084811 hasAuthorship W3082084811A5007550309 @default.
• W3082084811 hasAuthorship W3082084811A5014671025 @default.
• W3082084811 hasAuthorship W3082084811A5015003014 @default.
• W3082084811 hasAuthorship W3082084811A5017520870 @default.
• W3082084811 hasAuthorship W3082084811A5025416634 @default.
• W3082084811 hasAuthorship W3082084811A5030515491 @default.
• W3082084811 hasAuthorship W3082084811A5040195943 @default.
• W3082084811 hasAuthorship W3082084811A5043046640 @default.
• W3082084811 hasAuthorship W3082084811A5044945171 @default.
• W3082084811 hasAuthorship W3082084811A5048241163 @default.
• W3082084811 hasAuthorship W3082084811A5069464289 @default.
• W3082084811 hasAuthorship W3082084811A5073819873 @default.
• W3082084811 hasAuthorship W3082084811A5077867618 @default.
• W3082084811 hasAuthorship W3082084811A5083527183 @default.
• W3082084811 hasAuthorship W3082084811A5084740033 @default.
• W3082084811 hasAuthorship W3082084811A5085784504 @default.
• W3082084811 hasAuthorship W3082084811A5088403164 @default.
• W3082084811 hasAuthorship W3082084811A5088791005 @default.
• W3082084811 hasAuthorship W3082084811A5089094058 @default.
• W3082084811 hasAuthorship W3082084811A5090148132 @default.
• W3082084811 hasBestOaLocation W30820848111 @default.
• W3082084811 hasConcept C104317684 @default.
• W3082084811 hasConcept C121608353 @default.
• W3082084811 hasConcept C126322002 @default.
• W3082084811 hasConcept C143998085 @default.
• W3082084811 hasConcept C167135981 @default.
• W3082084811 hasConcept C185592680 @default.
• W3082084811 hasConcept C207103383 @default.
• W3082084811 hasConcept C2776256026 @default.
• W3082084811 hasConcept C2777542201 @default.
• W3082084811 hasConcept C2781182431 @default.
• W3082084811 hasConcept C30481170 @default.
• W3082084811 hasConcept C44249647 @default.
• W3082084811 hasConcept C55493867 @default.
• W3082084811 hasConcept C71924100 @default.
• W3082084811 hasConcept C90924648 @default.
• W3082084811 hasConceptScore W3082084811C104317684 @default.
• W3082084811 hasConceptScore W3082084811C121608353 @default.
• W3082084811 hasConceptScore W3082084811C126322002 @default.
• W3082084811 hasConceptScore W3082084811C143998085 @default.
• W3082084811 hasConceptScore W3082084811C167135981 @default.
• W3082084811 hasConceptScore W3082084811C185592680 @default.
• W3082084811 hasConceptScore W3082084811C207103383 @default.
• W3082084811 hasConceptScore W3082084811C2776256026 @default.
• W3082084811 hasConceptScore W3082084811C2777542201 @default.
• W3082084811 hasConceptScore W3082084811C2781182431 @default.
• W3082084811 hasConceptScore W3082084811C30481170 @default.

• next